Abstract:Huan Xue, 1, &ast Hao-Jie Xing, 1, &ast Bin Wang, 1 Chao Fu, 1 Yu-Shan Zhang, 1 Xi Qiao, 1 Chao Guo, 1 Xiao-Li Zhang, 1 Bin Hu, 1 Xin Zhao, 1 Li-Jiao Deng, 1 Xiao-Chan Zhu, 1 Yi Zhang, 1 Yun-Feng Liu 2 1 Department of Pharmacology, Shanxi Medical University, Taiyuan, 030001, People's Republic of China; 2 Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yi Zhang; Yun-Feng Liu, Tel +86-18835102847 ; +86-18703416169, Email ; Purpose: The glucagon-like peptide-1 receptor (GLP-1R) is an effective therapeutic target for type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). Research has focused on small-molecule GLP-1R agonists because of their ease of use in oral formulations and improved patient compliance. However, no small-molecule GLP-1R agonists are currently available in the market. We aimed to screen for a potential oral small-molecule GLP-1R agonist and evaluated its effect on blood glucose and NASH. Methods: The Connectivity map database was used to screen for candidate small-molecule compounds. Molecular docking was performed using SYBYL software. Rat pancreatic islets were incubated in different concentrations glucose solutions, with cinchonine or Exendin (9– 39) added to determine insulin secretion levels. C57BL/6 mice, GLP-1R −/− mice and hGLP-1R mice were used to conduct oral glucose tolerance test. In addition, we fed ob/ob mice with the GAN diet to induce the NASH model. Cinchonine (50 mg/kg or 100 mg/kg) was administered orally twice daily to the mice. Serum liver enzymes were measured using biochemical analysis. Liver tissues were examined using Hematoxylin-eosin staining, Oil Red O staining and Sirius Red staining. Results: Based on the small intestinal transcriptome of geniposide, a recognized small-molecule GLP-1R agonist, we identified that cinchonine exerted GLP-1R agonist-like effects. Cinchonine had a good binding affinity for GLP-1R. Cinchonine promoted glucose-dependent insulin secretion, which could be attenuated significantly by Exendin (9– 39), a specific GLP-1R antagonist. Moreover, cinchonine could reduce blood glucose in C57BL/6 and hGLP-1R mice, an effect that could be inhibited with GLP-1R knockout. In addition, cinchonine reduced body weight gain and food intake in ob/ob-GAN NASH mice dose-dependently. 100 mg/kg cinchonine significantly improved liver function by reducing the ALT, ALP and LDH levels. Importantly, 100 mg/kg cinchonine ameliorated hepatic steatosis and fibrosis in NASH mice. Conclusion: Cinchonine, a potential oral small-molecule GLP-1R agonist, could reduce blood glucose and ameliorate NASH, providing a strategy for developing small-molecule GLP-1R agonists. Graphical Keywords: glucagon-like peptide-1 receptor, cinchonine, drug repurposing, non-alcoholic steatohepatitis, type 2 diabetes mellitus Graphical Diabetes is a major threat to human health worldwide. 1 The International Diabetes Federation (IDF) has listed approximately 537 million adults with diabetes in 2021, a number expected to increase to 643 million by 2030. 2 Glucagon-like peptide-1 receptor (GLP-1R) agonists have shown remarkable therapeutic effects for type 2 diabetes mellitus (T2DM). 3,4 Furthermore, GLP-1R agonists have multiple biological effects that can treat obesity, cardiovascular, neurological, metabolic diseases and play a positive role in tumor therapy. 5 Non-alcoholic fatty liver disease (NAFLD) ranges from simple liver steatosis at the initial stage to non-alcoholic steatohepatitis (NASH), which, if not controlled, can further develop into cirrhosis and hepatocellular cancer, seriously threatening human health. 6 GLP-1R agonists are important candidates for the treatment of NASH. 7,8 However, the clinical GLP-1R agonists are macromolecular peptide preparations. 9 They should be administrated by injection except for oral semaglutide, limiting their clinical application. 10–12 Compared to peptides, small-molecule compounds are easier to develop into oral preparations and improve patient compliance. 13–15 Hence, small-molecule GLP-1R agonists are highly desirable. However, no small-molecule GLP-1R agonist is available. In recent years, the cost of traditional drug development has increased significantly. In addition, the development cycles are long and the success rate is low, which ar -Abstract Truncated-

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals

Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion

A GLP‐1/glucagon/CCK‐2 receptors tri‐agonist provides new therapy for obesity and diabetes

GLP-1R mediates idebenone-reduced blood glucose in mice

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency

A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects

788-P: Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models

Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action

1625-P: GS-4571, an Oral Small Molecule GLP-1R Agonist, Improves Glucose Tolerance and Suppresses Food Intake in Obese Diabetic Cynomolgus Monkeys

Hepatic Glucagon Receptor Binding and Glucose-Lowering in Vivo by Peptidyl and Non-Peptidyl Glucagon Receptor Antagonists.

Discovery of an Insulin-Induced Gene Binding Compound That Ameliorates Nonalcoholic Steatohepatitis by Inhibiting Sterol Regulatory Element-Binding Protein-Mediated Lipogenesis.

789-P: Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity

SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent “Compound 2” at the GLP-1 Receptor